公开(公告)号：US20240255517A1

公开(公告)日：2024-08-01

申请号：US18565193

申请日：2022-06-03

Applicant: Elektrofi, Inc.

Inventor： Tyler L. Carter ,  Lyndon Fitzgerald Charles, Jr. ,  Chase Spenser Coffman ,  Daniel Benjamin Dadon ,  Zishu Gui ,  Sadiqua Shadbar ,  Chaitanya Sudrik ,  Yi Tang

IPC: G01N33/68

CPC classification number: G01N33/6803

Abstract: The present disclosure provides screening methods to predict stability of proteins in particle formulations during early stage drug development. In particular, the screening methods disclosed herein uses high throughput protocols that allow rapid identification of stable proteins in the particle formulations in a cost effective manner.

公开(公告)号：US20230338299A1

公开(公告)日：2023-10-26

申请号：US18344142

申请日：2023-06-29

Applicant: Elektrofi, Inc.

Inventor： Paul Brown ,  Lyndon Fitzgerald Charles, JR. ,  Chase Spenser Coffman ,  Daniel Benjamin Dadon ,  James W. Ivey ,  Lisa Liu ,  Chaitanya Sudrik

IPC: A61K9/51 ,  C07K16/00

CPC classification number: A61K9/51 ,  C07K16/00

Abstract: The present disclosure relates to compositions and methods that enable the formation of pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled formation of circular particles having low internal void spaces comprising bioactive therapeutic agents.

公开(公告)号：US20200253875A1

公开(公告)日：2020-08-13

申请号：US16633097

申请日：2018-07-25

Applicant: Elektrofi, Inc.

Inventor： Chase Spenser Coffman ,  Lyndon Fitzgerald Charles, Jr. ,  Paul Brown ,  Daniel Benjamin Dadon ,  Lisa Liu ,  Cory Robinson ,  Dale Arlington Thomas, III

IPC: A61K9/14 ,  B01J2/06

Abstract: The invention provides methods for the preparation of particles including one or more agents, e.g., therapeutic or diagnostic agents. The particles can be formed by creating droplets of a first liquid, e.g., including an agent, and removing the first liquid, e.g., through its dispersal in a second liquid and/or evaporation, to solidify the droplets. Advantageously, the process of forming the particles does not significantly alter the structure or activity of the agents and may enhance the stability of the agents. For example, the particles may be stored for long periods of time without significant loss of activity, and in some embodiments, without the need for refrigeration. These particles may be used to generate stabilized pharmaceutical compositions for storage or other logistical purposes, pharmaceutical suspensions, pharmaceutical powder formulations (e.g., inhalable powders, injectable powders), creams or other topical pastes, nutraceuticals, or cosmetics.